1. |
Del Prete M, Fiore F, Modica R, et al.Hepatic arterial embolization in patients with neuroendocrine tumors[J].J Exp Clin Cancer Res, 2014, 33:43.
|
2. |
Harring TR, Nguyen NT, Goss JA, et al.Treatment of liver metastases in patients with neuroendocrine tumors:a comprehensive review[J].Int J Hepatol, 2011, 2011:154541.
|
3. |
John BJ, Davidson BR.Treatment options for unresectable neuroendocrine liver metastases[J].Expert Rev Gastroenterol Hepatol, 2012, 6(3):357-369.
|
4. |
Ito T, Igarashi H, Jensen RT.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs):recent insights and advances[J].J Gastroenterol, 2012, 47(9):941-960.
|
5. |
Rindi G, Capella C, Solcia E.Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract[J].Q J Nucl Med, 2000, 44(1):13-21.
|
6. |
Rindi G, Arnold R, Bosman FT, et al.Nomenclature and classification of neuroendocrine neoplasms of the digestive system//Bosman T, Carneiro F, Hruban R, et al.WHO classification of tumours of the digestive system[M].4th ed.Lyon, France:International Agency for Research on Cancer (IARC), 2010:13-14.
|
7. |
Rindi G, Klöppel G, Alhman H, et al.TNM staging of foregut (neuro) endocrine tumors:a consensus proposal including a grading system[J].Virchows Arch, 2006, 449(4):395-401.
|
8. |
Mayo SC, de Jong MC, Pulitano C, et al.Surgical management of hepatic neuroendocrine tumor metastasis:results from an international multi-institutional analysis[J].Ann Surg Oncol, 2010, 17(12):3129-3136.
|
9. |
Frilling A, Li J, Malamutmann E, et al.Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease[J].Br J Surg, 2009, 96(2):175-184.
|
10. |
Sarmiento JM, Heywood G, Rubin J, et al.Surgical treatment of neuroendocrine metastases to the liver:a plea for resection to increase survival[J].J Am Coll Surg, 2003, 197(1):29-37.
|
11. |
Oberg K, Eriksson B.Endocrine tumours of the pancreas[J].Best Pract Res Clin Gastroenterol, 2005, 19(5):753-781.
|
12. |
Glazer ES, Tseng JF, Al-Refaie W, et al.Long-term survival after surgical management of neuroendocrine hepatic metastases[J].HPB (Oxford), 2010, 12(6):427-433.
|
13. |
Cheung TT, Chok KS, Chan AC, et al.Long term survival analysis of hepatectomy for neuroendocrine tumour liver metastases[J].Sci World J, 2014, 2014:524045.
|
14. |
Tsuchikawa T, Hirano S, Tanaka E, et al.Surgical strategy for liver metastases of neuroendocrine tumors[J].Hepatogastroenterology, 2012, 59(115):921-923.
|
15. |
Mayo SC, Cameron AM, Pawlik TM.Neuroendocrine liver metastasis:transplant as part of multimodality liver-directed therapy[J].Arch Surg, 2012, 147(1):98-99.
|
16. |
Frilling A, Modlin IM, Kidd M, et al.Recommendations for management of patients with neuroendocrine liver metastases[J].Lancet Oncol, 2014, 15(1):e8-e21.
|
17. |
Elias D, Lefevre JH, Duvillard P, et al.Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination:they are many more than you think[J].Ann Surg, 2010, 251(2):307-310.
|
18. |
Contessa JN, Griffith KA, Wolff E, et al.Radiotherapy for pancreatic neuroendocrine tumors[J].Int J Radiat Oncol Biol Phys, 2009, 75(4):1196-1200.
|
19. |
Gupta S, Johnson MM, Murthy R, et al.Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors:variables affecting response rates and survival[J].Cancer, 2005, 104(8):1590-1602.
|
20. |
Kennedy AS, Dezarn WA, Mcneillie P, et al.Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres:early results in 148 patients[J].Am J Clin Oncol, 2008, 31(3):271-279.
|
21. |
Ezziddin S, Meyer C, Kahancova S, et al.90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy[J].J Nucl Med, 2012, 53(11):1663-1669.
|
22. |
Bester L, Meteling B, Pocock N, et al.Radioembolization versus standard care of hepatic metastases:comparative retrospective cohort study of survival outcomes and adverse events in salvage patients[J].J Vasc Interv Radiol, 2012, 23(1):96-105.
|
23. |
Pfeifer AK, Gregersen T, Grønbæk H, et al.Peptide receptor radionuclide therapy with Y-DOTATOC and (177) Lu-DOTATOC in advanced neuroendocrine tumors:results from a Danish cohort treated in Switzerland[J].Neuroendocrinology, 2011, 93(3):189-196.
|
24. |
陈永辉, 贾兵, 李方, 等.肽受体放射性核素治疗进展期胰腺神经内分泌肿瘤[J].癌症进展, 2010, 8(6):598-601.
|
25. |
Ravaioli M, Ercolani G, Neri F, et al.Liver transplantation for hepatic tumors:a systematic review[J].World J Gastroenterol, 2014, 20(18):5345-5352.
|
26. |
Lewis MA, Hubbard J.Multimodal liver-directed management of neuroendocrine hepatic metastases[J].Int J Hepatol, 2011, 2011:452343.
|
27. |
Le Treut YP, Grégoire E, Belghiti J, et al.Predictors of long-term survival after liver transplantation for metastatic endocrine tumors:an 85-case French multicentric report[J].Am J Transplant, 2008, 8(6):1205-1213.
|
28. |
Mazzaferro V, Pulvirenti A, Coppa J.Neuroendocrine tumors metastatic to the liver:how to select patients for liver transplantation?[J].J Hepatol, 2007, 47(4):460-466.
|
29. |
Mccormick B, Ottesen RA, Hughes ME, et al.Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer:practice patterns at National Comprehensive Cancer Network Institutions[J].J Am Coll Surg, 2014, [Epub ahead of print].
|
30. |
Kong G, Thompson M, Collins M, et al.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)[J].Eur J Nucl Med Mol Imaging, 2014, [Epub ahead of print].
|
31. |
Panzuto F, Rinzivillo M, Fazio N, et al.Real-world study of everolimus in advanced progressive neuroendocrine tumors[J].Oncologist, 2014, [Epub ahead of print].
|
32. |
Caplin ME, Pavel M, Ćwikła JB, et al.Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J].N Engl J Med, 2014, 371(3):224-233.
|
33. |
Toumpanakis C, Caplin ME.Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors[J].Semin Oncol, 2013, 40(1):56-68.
|
34. |
朱优龙, 姜波健, 俞继卫.mTOR及其信号通路在胃癌化疗耐药中的研究进展[J].中国普外基础与临床杂志, 2012, 19(12):1352-1356.
|
35. |
Briest F, Grabowski P.PI3K-AKT-mTOR-signaling and beyond:the complex network in gastroenteropancreatic neuroendocrine neoplasms[J].Theranostics, 2014, 4(4):336-365.
|
36. |
Yao JC, Phan A, Hoff PM, et al.Targeting vascular endothelial growth factor in advanced carcinoid tumor:a random assignment phaseⅡstudy of depot octreotide with bevacizumab and pegylated interferon alpha-2b[J].J Clin Oncol, 2008, 26(8):1316-1323.
|
37. |
Blumenthal GM, Cortazar P, Zhang JJ, et al.FDA approval summary:sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors[J].Oncologist, 2012, 17(8):1108-1113.
|
38. |
Vinik AI, Raymond E.Pancreatic neuroendocrine tumors:approach to treatment with focus on sunitinib[J].Therap Adv Gastroenterol, 2013, 6(5):396-411.
|